BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

990 related articles for article (PubMed ID: 29538647)

  • 1. Longitudinal tau PET in ageing and Alzheimer's disease.
    Jack CR; Wiste HJ; Schwarz CG; Lowe VJ; Senjem ML; Vemuri P; Weigand SD; Therneau TM; Knopman DS; Gunter JL; Jones DT; Graff-Radford J; Kantarci K; Roberts RO; Mielke MM; Machulda MM; Petersen RC
    Brain; 2018 May; 141(5):1517-1528. PubMed ID: 29538647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.
    Lowe VJ; Wiste HJ; Senjem ML; Weigand SD; Therneau TM; Boeve BF; Josephs KA; Fang P; Pandey MK; Murray ME; Kantarci K; Jones DT; Vemuri P; Graff-Radford J; Schwarz CG; Machulda MM; Mielke MM; Roberts RO; Knopman DS; Petersen RC; Jack CR
    Brain; 2018 Jan; 141(1):271-287. PubMed ID: 29228201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
    Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting future rates of tau accumulation on PET.
    Jack CR; Wiste HJ; Weigand SD; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Vemuri P; Mielke MM; Whitwell J; Josephs K; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
    Brain; 2020 Oct; 143(10):3136-3150. PubMed ID: 33094327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau positron emission tomography in preclinical Alzheimer's disease.
    Insel PS; Young CB; Aisen PS; Johnson KA; Sperling RA; Mormino EC; Donohue MC
    Brain; 2023 Feb; 146(2):700-711. PubMed ID: 35962782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
    Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
    Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
    Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
    JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early stages of tau pathology and its associations with functional connectivity, atrophy and memory.
    Berron D; Vogel JW; Insel PS; Pereira JB; Xie L; Wisse LEM; Yushkevich PA; Palmqvist S; Mattsson-Carlgren N; Stomrud E; Smith R; Strandberg O; Hansson O
    Brain; 2021 Oct; 144(9):2771-2783. PubMed ID: 33725124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
    Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR;
    JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes.
    Sintini I; Graff-Radford J; Senjem ML; Schwarz CG; Machulda MM; Martin PR; Jones DT; Boeve BF; Knopman DS; Kantarci K; Petersen RC; Jack CR; Lowe VJ; Josephs KA; Whitwell JL
    Brain; 2020 Jul; 143(7):2281-2294. PubMed ID: 32572464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles.
    Pascoal TA; Therriault J; Benedet AL; Savard M; Lussier FZ; Chamoun M; Tissot C; Qureshi MNI; Kang MS; Mathotaarachchi S; Stevenson J; Hopewell R; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2020 Sep; 143(9):2818-2830. PubMed ID: 32671408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
    Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
    Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Binette AP; Vogel JW; Klein G; Borroni E; Tonietto M; Strandberg O; Mattsson-Carlgren N; Palmqvist S; Pontecorvo MJ; Iaccarino L; Stomrud E; Ossenkoppele R; Smith R; Hansson O;
    JAMA Neurol; 2023 Jun; 80(6):614-623. PubMed ID: 37155176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
    Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
    Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
    Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
    Groot C; Smith R; Stomrud E; Binette AP; Leuzy A; Wuestefeld A; Wisse LEM; Palmqvist S; Mattsson-Carlgren N; Janelidze S; Strandberg O; Ossenkoppele R; Hansson O
    Brain; 2023 Apr; 146(4):1580-1591. PubMed ID: 36084009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
    Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.